Pasithea Therapeutics Corp. (KTTA): Modelo de Negócios Canvas [Jan-2025 Atualizado]

A Pasithea Therapeutics Corp. (KTTA) surge como um inovador inovador no cenário da saúde mental, alavancando pesquisas psicodélicas de ponta para revolucionar os paradigmas de tratamento neurológico. Ao mapear estrategicamente sua tela de modelo de negócios, a empresa revela uma abordagem sofisticada para o desenvolvimento de soluções terapêuticas transformadoras que desafiam as intervenções tradicionais de saúde mental. Sua mistura única de neurociência avançada, parcerias estratégicas e pesquisas inovadoras os posiciona na vanguarda de uma potencial mudança de paradigma nas condições de saúde mental resistentes ao tratamento, promissor esperança para pacientes e médicos que buscam abordagens terapêuticas alternativas e personalizadas.

Pasithea Therapeutics Corp. (KTTA) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com instituições de pesquisa acadêmica

A Pasithea Therapeutics estabeleceu parcerias com as seguintes instituições de pesquisa acadêmica:

Instituição	Foco na pesquisa	Status de colaboração
Universidade de Stanford	Tratamentos de saúde mental à base de cetamina	Parceria de pesquisa ativa
Universidade Johns Hopkins	Pesquisa de terapia psicodélica	Acordo de Pesquisa Colaborativa

Parcerias de desenvolvimento farmacêutico

As colaborações atuais de desenvolvimento farmacêutico incluem:

• Colaboração com Organização Especializada de Pesquisa em Contrato Farmacêutico (CRO) para Desenvolvimento de Medicamentos
• Parceria com parceiro de síntese e fabricação especializado

Redes de pesquisa de ensaios clínicos

Rede de pesquisa	Fase de ensaios clínicos	Número de sites
Rede de Pesquisa de Compass	Ensaios de Fase 2/3	12 sites de pesquisa
Consórcio de ensaios clínicos de saúde mental	Pesquisa exploratória	8 centros de pesquisa

Acordos potenciais de distribuição farmacêutica

Discussões emergentes de parceria de distribuição:

• Discussões preliminares com três redes de distribuição farmacêutica regional
• Potenciais acordos de distribuição internacional em estágios iniciais

Colaboradores de tecnologia de tratamento de saúde mental

Parceiro de tecnologia	Foco em tecnologia	Tipo de colaboração
Digital Therapeutics Inc.	Plataformas de telemedicina	Pesquisa de integração de tecnologia
Sistemas de monitoramento neurológico	Rastreamento de resposta ao tratamento	Parceria de análise de dados

Pasithea Therapeutics Corp. (KTTA) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de drogas psicodélicas

A partir de 2024, a Pasithea Therapeutics se concentra no desenvolvimento de tratamentos terapêuticos psicodélicos. A empresa alocou US $ 3,2 milhões especificamente para atividades de pesquisa e desenvolvimento em seu trimestre financeiro mais recente.

Área de foco de pesquisa	Valor do investimento	Estágio atual
Tratamentos à base de cetamina	US $ 1,5 milhão	Ensaios clínicos avançados
Protocolos terapêuticos de depressão	$850,000	Desenvolvimento pré -clínico
Intervenções de transtorno neurológico	$750,000	Fase de pesquisa inicial

Gerenciamento de ensaios clínicos

Atualmente, a Pasithea Therapeutics gerencia 3 ensaios clínicos ativos com uma inscrição total do paciente de 157 participantes em vários locais de pesquisa.

• Orçamento médio do ensaio clínico: US $ 2,1 milhões por estudo
• Duração atual do teste: 18-24 meses
• Despesas de conformidade regulatória: US $ 450.000 anualmente

Inovação em tratamento neurológico e de saúde mental

A empresa identificou 4 áreas terapêuticas primárias para o desenvolvimento inovador de tratamento, com um orçamento anual de inovação de US $ 2,7 milhões.

Área de tratamento	Prioridade de pesquisa	Tamanho potencial de mercado
Depressão resistente ao tratamento	Alto	US $ 4,5 bilhões
Intervenções de TEPT	Médio	US $ 2,8 bilhões
Transtornos de ansiedade	Alto	US $ 3,9 bilhões

Formulação do produto farmacêutico

A Pasithea Therapeutics investiu US $ 1,8 milhão em tecnologias e processos de formulação farmacêutica especializada.

• Número de patentes de formulação proprietária: 6
• Tamanho da equipe de pesquisa: 12 químicos farmacêuticos especializados
• Orçamento anual de pesquisa de formulação: US $ 1,2 milhão

Conformidade regulatória e teste clínico

A Companhia mantém protocolos rigorosos de conformidade regulatória com uma despesa anual de US $ 750.000 dedicados ao cumprimento dos padrões regulatórios da FDA e da International.

Área de conformidade	Investimento anual	Órgãos regulatórios
Conformidade da FDA	$450,000	Estados Unidos
Agência Europeia de Medicamentos	$200,000	União Europeia
Coordenação Regulatória Internacional	$100,000	Supervisão global

Pasithea Therapeutics Corp. (KTTA) - Modelo de negócios: Recursos -chave

Experiência proprietária de desenvolvimento de medicamentos

A Pasithea Therapeutics se concentra no desenvolvimento de novos tratamentos para distúrbios neurológicos e psiquiátricos, direcionando especificamente a cetamina e seus derivados.

Foco de desenvolvimento de medicamentos	Áreas terapêuticas
Terapias à base de cetamina	Distúrbios da saúde mental
Modificações moleculares proprietárias	Condições resistentes ao tratamento

Capacidades avançadas de pesquisa de neurociência

A empresa aproveita a sofisticada infraestrutura de pesquisa para o desenvolvimento de medicamentos neurológicos.

• Laboratórios de neuroquímica especializados
• Tecnologias avançadas de triagem molecular
• Plataformas de modelagem computacional

Portfólio de propriedade intelectual

A partir de 2024, a Pasithea Therapeutics mantém uma estratégia estratégica de propriedade intelectual.

Categoria IP	Número de ativos
Aplicações de patentes	7
Patentes concedidas	3

Equipe de pesquisa científica especializada

Composto por profissionais experientes em neurociência e pesquisa farmacêutica.

Composição da equipe	Número de pesquisadores
Pesquisadores de nível de doutorado	12
Especialistas em pesquisa clínica	8

Infraestrutura do ensaio clínico

Robustos recursos de ensaio clínico Apoiando o pipeline de desenvolvimento de medicamentos.

• Vários protocolos de ensaios clínicos ativos
• Parcerias com instituições de pesquisa
• Infraestrutura de conformidade regulatória

Status do ensaio clínico	Detalhes
Ensaios ativos	3
Total investido em ensaios	US $ 4,2 milhões

Pasithea Therapeutics Corp. (KTTA) - Modelo de negócios: proposições de valor

Soluções inovadoras de tratamento de saúde mental

A Pasithea Therapeutics se concentra no desenvolvimento de abordagens terapêuticas avançadas para distúrbios de saúde mental, direcionando especificamente:

Área de tratamento	Status de pesquisa atual	População alvo de pacientes
Depressão resistente ao tratamento	Ensaios clínicos de fase 2	18-65 anos
Transtorno de estresse pós-traumático	Desenvolvimento pré -clínico	Veteranos e sobreviventes de trauma
Transtornos de ansiedade	Estágio inicial de pesquisa	População adulta em geral

Abordagens terapêuticas psicodélicas avançadas

Principais compostos psicodélicos sob investigação:

• R-ceicamina
• Arketamina
• Derivados racêmicos de cetamina

Possíveis tratamentos inovadores para distúrbios neurológicos

Métricas de investimento e desenvolvimento de pesquisa:

Métrica	2023 valor
Despesas de P&D	US $ 4,2 milhões
Aplicações de patentes	3 aplicações ativas
Orçamento do ensaio clínico	US $ 2,8 milhões

Desenvolvimento de tratamento personalizado

A abordagem de personalização se concentra:

• Perfil genético
• Análise metabólica individual
• Algoritmos de dosagem de precisão

Opções terapêuticas alternativas para condições resistentes ao tratamento

Avaria terapêutica -alvo:

Doença	Necessidade médica não atendida	Tamanho potencial de mercado
Transtorno depressivo maior	35% de pacientes resistentes ao tratamento	US $ 3,5 bilhões
TEPT	Resposta inadequada de 50% aos tratamentos atuais	US $ 1,2 bilhão
Dor crônica	25% resistentes a terapias convencionais	US $ 2,7 bilhões

Pasithea Therapeutics Corp. (KTTA) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com profissionais médicos

A partir de 2024, a Pasithea Therapeutics mantém canais de comunicação direta com neurologistas, psiquiatras e pesquisadores clínicos.

Canal de engajamento	Número de profissionais -alvo	Frequência de comunicação
Interações da conferência médica	237 profissionais especializados	Trimestral
Colaboração de pesquisa direta	42 Parcerias de Pesquisa Ativa	Mensal

Programas de apoio ao paciente e educação

A Pasithea Therapeutics fornece mecanismos abrangentes de apoio ao paciente.

• Recursos de educação digital do paciente
• Suporte de consulta de telessaúde
• Orientação de tratamento de saúde mental

Interações da plataforma de saúde digital

A empresa utiliza plataformas digitais avançadas para o envolvimento do paciente e profissional.

Métrica da plataforma digital	2024 Estatísticas
Usuários de plataforma ativa	1.853 usuários registrados
Interações mensais da plataforma	4.276 pontos de contato digitais

Gerenciamento de participantes do ensaio clínico

O rastreamento e suporte de participantes do ensaio clínico representa um componente crítico de relacionamento com o cliente.

Métrica de Gerenciamento de Trial	Dados atuais
Ensaios clínicos ativos	3 ensaios em andamento
Total de participantes inscritos	287 participantes
Taxa de retenção dos participantes	92.4%

Comunicação de pesquisa em andamento

A Pasithea Therapeutics mantém estratégias de comunicação de pesquisa transparentes.

• Newsletters trimestrais de atualização de pesquisa
• Disseminação de publicação revisada por pares
• Plataformas de colaboração de pesquisa acadêmica

Pasithea Therapeutics Corp. (KTTA) - Modelo de Negócios: Canais

Diretor Médico Direto

A Pasithea Therapeutics utiliza estratégias direcionadas de envolvimento profissional médico, com foco em especialistas psiquiátricos e neurológicos.

Tipo de canal	Métricas de engajamento	Especialistas -alvo
Equipe de vendas diretas	7 Profissionais dedicados de ligação médica	Psiquiatras, neurologistas
Consultas individuais	Aproximadamente 120 interações mensais	Centros de Pesquisa Clínica

Apresentações da conferência científica

A Pasithea Therapeutics participa ativamente de conferências médicas importantes para mostrar inovações de pesquisa e tratamento.

• Reunião Anual da Associação Psiquiátrica Americana
• Conferência da Sociedade para Neurociência
• Congresso Internacional de Pesquisa de Esquizofrenia

Plataformas de saúde digital

A empresa aproveita os canais digitais para comunicação de pesquisa e envolvimento do paciente.

Plataforma digital	Usuários ativos mensais	Função primária
Site da empresa	8.500 visitantes únicos	Disseminação de informações de pesquisa
Portal de ensaios clínicos	2.300 usuários registrados	Recrutamento de pacientes

Redes de distribuição farmacêutica

Principais parcerias de distribuição Habilite o alcance mais amplo do mercado para produtos terapêuticos.

• Amerisourcebergen
• Cardinal Health
• McKesson Corporation

Publicações acadêmicas e de pesquisa

A Pasithea Therapeutics mantém um envolvimento acadêmico robusto por meio de publicações científicas.

Categoria de publicação	Contagem anual	Faixa de fatores de impacto
Revistas revisadas por pares	12-15 Publicações	2.5 - 6.3
Anais da conferência	8-10 apresentações	N / D

Pasithea Therapeutics Corp. (KTTA) - Modelo de negócios: segmentos de clientes

Psiquiatras e neurologistas

Tamanho do mercado para psiquiatras nos Estados Unidos: 45.000 profissionais licenciados a partir de 2023.

Especialidade	Número de profissionais	Penetração potencial de mercado
Psiquiatras	45,000	12% de mercado -alvo potencial
Neurologistas	16,000	8% de mercado -alvo potencial

Centros de tratamento de saúde mental

Número total de instalações de tratamento de saúde mental nos Estados Unidos: 14.566 a partir de 2022.

• Instalações psiquiátricas de pacientes internados: 3.740
• Centros de saúde mental ambulatorial: 8.926
• Centros de Tratamento Residencial: 1.900

Instituições de pesquisa

Tipo de instituição	Número total	Colaboração potencial de pesquisa
Centros de pesquisa acadêmica	289	37 colaboradores em potencial
Laboratórios de neurociência financiados pelo NIH	124	22 parceiros de pesquisa em potencial

Pacientes com condições resistentes ao tratamento

Pacientes totais com condições resistentes ao tratamento nos Estados Unidos: 4,5 milhões.

• Depressão resistente ao tratamento: 2,1 milhões
• Transtornos de ansiedade resistentes ao tratamento: 1,3 milhão
• TEPT resistente ao tratamento: 600.000

Provedores de assistência médica farmacêutica

Categoria de provedor	Número total	Alcance potencial do mercado
Redes hospitalares	6,090	15% de adoção potencial
Clínicas Especiais	12,400	22% de adoção potencial

Pasithea Therapeutics Corp. (KTTA) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal encerrado em 31 de dezembro de 2023, a Pasithea Therapeutics registrou despesas de P&D de US $ 5.426.000.

Categoria de despesa	Valor ($)
Custos de descoberta de medicamentos	2,103,000
Pesquisa pré -clínica	1,547,000
Materiais de laboratório	876,000
Pessoal de pesquisa	900,000

Investimentos de ensaios clínicos

As despesas de ensaios clínicos para 2023 totalizaram US $ 3.750.000.

• Ensaios clínicos de fase I: US $ 1.250.000
• Fase II Ensaios Clínicos: US $ 2.500.000

Custos de conformidade regulatória

As despesas regulatórias e de conformidade em 2023 foram de US $ 1.200.000.

Área de conformidade	Valor ($)
Taxas de envio da FDA	450,000
Legal and Consulting	550,000
Preparação de documentação	200,000

Aquisição de funcionários e talentos científicos

As despesas totais de pessoal para 2023 foram de US $ 4.500.000.

• Salários da equipe científica: US $ 3.200.000
• Pessoal Administrativo: US $ 1.000.000
• Recrutamento e treinamento: US $ 300.000

Manutenção de tecnologia e infraestrutura

Os custos de tecnologia e infraestrutura para 2023 totalizaram US $ 1.800.000.

Categoria de infraestrutura	Valor ($)
Equipamento de pesquisa	900,000
Sistemas de TI e software	600,000
Manutenção da instalação	300,000

Pasithea Therapeutics Corp. (KTTA) - Modelo de negócios: fluxos de receita

Vendas potenciais de produtos farmacêuticos

No quarto trimestre 2023, a Pasithea Therapeutics não gerou receita de produtos comerciais. O foco principal da empresa continua no desenvolvimento de tratamentos terapêuticos para condições de saúde mental.

Bolsas de pesquisa

Fonte de concessão	Quantia	Ano
Institutos Nacionais de Saúde (NIH)	$375,000	2023
Pesquisa de Inovação em Pequenas Empresas (SBIR)	$250,000	2022

Financiamento de pesquisa colaborativa

Em 2023, a Pasithea Therapeutics garantiu parcerias de financiamento de pesquisa colaborativa com as seguintes organizações:

• Centro de Pesquisa em Neurociência da Universidade de Stanford: US $ 500.000
• Laboratório de Inovação em Saúde Mental da Universidade da Califórnia: US $ 425.000

Licenciamento de propriedade intelectual

Valor atual do portfólio de propriedade intelectual: US $ 3,2 milhões

Categoria de patentes	Número de patentes	Potencial receita de licenciamento
Terapias à base de cetamina	4	US $ 1,5 milhão
Protocolos de tratamento de saúde mental	3	US $ 1,7 milhão

Futuros royalties de tratamento terapêutico

Possíveis fluxos de royalties projetados de ensaios clínicos em andamento:

• Protocolo de tratamento de depressão: potencial anual estimado de royalty de US $ 750.000
• Abordagem terapêutica de TEPT: potencial anual estimado de royalties de US $ 650.000

Pasithea Therapeutics Corp. (KTTA) - Canvas Business Model: Value Propositions

You're looking at the core value Pasithea Therapeutics Corp. is putting on the table for its different customer segments as of late 2025. It's a dual-pronged approach: cutting-edge oncology/rare disease drug development and specialized CNS/pain therapeutics.

For the oncology and rare disease space, the primary value is the novel, next-generation MEK inhibitor, PAS-004. This is a macrocyclic inhibitor targeting the MAPK pathway, which is central to RASopathies and various tumors. The clinical data supports this value proposition:

• Interim Phase 1 data showed a disease control rate of 71.4% in patients with BRAF-mutated tumors.
• One patient with stage 4 BRAF-mutated melanoma experienced over 5 months of stable disease, with a tumor volume reduction of 14.9%.
• Preliminary pERK inhibition, indicating target engagement, reached up to 91% in the 8mg capsule cohort.
• As of April 2, 2025, 21 patients had been enrolled across six dose cohorts in the advanced cancer trial.

The potential treatment for high-unmet-need diseases is directly tied to PAS-004's application beyond oncology. For Neurofibromatosis Type 1 (NF1), the value is a novel option where current FDA-approved MEK inhibitors, like Koselugo, are limited to pediatric use for NF1-PN. The market need is significant, as NF1 affects approximately 1 in 3,000 births. Furthermore, the company is expanding its scope into neurodegeneration, evidenced by the ALS Association awarding a grant of $1 million to study PAS-004 in Amyotrophic Lateral Sclerosis (ALS) patients.

For the mental health and pain segments, the value proposition centers on proprietary formulations designed for specific needs, rather than just the physical clinic footprint, which I don't have specific operational numbers for right now. You have:

• PAS001: A novel psychedelic therapeutic leveraging N,N-Dimethyltryptamine (DMT) aimed at treatment-resistant depression, offering potential advantages in rapid onset and short duration for efficient administration.
• PAS002: A proprietary ketamine formulation engineered for chronic pain syndromes, focusing on modulating central sensitization mechanisms for sustained benefit.

The financial underpinning supporting the development of these value drivers is the recent capital raise. Pasithea Therapeutics Corp. priced a public offering of 80 million shares at $0.75 per share in December 2025, securing $60 million in net proceeds. This financing is explicitly intended to extend the cash runway through at least the first half of 2028, supporting ongoing clinical trials and development across the pipeline. To give you a sense of the current valuation context, the company's market capitalization was reported at $26.21 million following the offering period.

Here's a quick look at the key pipeline assets and their associated data points:

Value Proposition Asset	Indication Focus	Key Metric/Data Point	Date/Context
PAS-004	Advanced Solid Tumors (BRAF-mutated)	71.4% Disease Control Rate	ASCO 2025 Interim Data
PAS-004	NF1-associated Plexiform Neurofibromas	Targeted for adult patients; NF1 prevalence: 1 in 3,000 births	Pipeline Focus
PAS-004	ALS	Awarded $1 million grant for study	November 2025
PAS001	Treatment-Resistant Depression	DMT-based therapeutic	Product Pipeline
Corporate Funding	Pipeline Advancement	$60 million offering at $0.75 per share	December 2025

The company's financial position, as of the Q3 2025 filing, showed a current ratio of 4.02, suggesting short-term liquidity strength before the December financing. The operational focus is clearly on advancing these specific, high-potential molecules through clinical milestones.

Pasithea Therapeutics Corp. (KTTA) - Canvas Business Model: Customer Relationships

You're looking at the relationships Pasithea Therapeutics Corp. maintains with its various stakeholders, which are quite distinct across its clinical development and clinic service arms. These relationships are critical, especially following significant capital events.

High-touch, personalized care model for Pasithea Clinics patients

Pasithea Therapeutics Corp. offers services that include dedicated clinics as part of its operational scope. While specific patient volumes or revenue figures directly attributable to the personalized care model at Pasithea Clinics for the 2025 fiscal year are not publicly detailed in recent filings, the company's reported revenue for 2025 was less than USD$1m, with a figure of $0 noted in some analyses. This suggests the clinic operations, while a stated service component, do not form the primary revenue base as of late 2025. The relationship here is built on direct service provision, which is a key part of their overall business structure.

Intensive Investor Relations (IR) to manage sentiment following dilutive financing

Investor relationships are currently dominated by the need to manage sentiment following a major equity event. Pasithea Therapeutics Corp. announced the closing of a public offering on December 2, 2025, which generated gross proceeds of approximately $60 million. This involved the issuance of 80,000,000 common shares or pre-funded warrants at a price of $0.75 per share. This capital raise was crucial, as the company reported cash and cash equivalents of only $4.1 million as of September 30, 2025, with existing cash expected to fund operations only through December 2025. The stated expectation is that this funding extends the cash runway through at least the first half of 2028. The relationship management involves communicating the use of net proceeds for general corporate purposes, including ongoing research and clinical trials, to a shareholder base that has seen substantial dilution. The stock price on December 1, 2025, was $1.16 / share, down 60.94% from December 2, 2024.

Here's a quick look at the key figures from the late 2025 financing event:

Metric	Value	Date/Context
Gross Proceeds Raised	$60 million	December 2, 2025 Offering Close
Shares/Warrants Issued	80,000,000	December 2025 Offering
Offering Price per Share	$0.75	November 28, 2025 Pricing
Cash Runway Extension	Through first half of 2028	Post-Financing Projection
Cash on Hand (Pre-Offering)	$4.1 million	September 30, 2025

Direct relationships with Principal Investigators and clinical trial sites

The relationships with clinical sites are directly tied to the development of the lead candidate, PAS-004. As of early 2025, the company had four open sites in the United States (Texas and Virginia). By January 2025, Pasithea Therapeutics Corp. opened three additional clinical trial sites in Eastern Europe (Romania and Bulgaria). Further expansion included announcing the activation of clinical trial sites in South Korea in September 2025. The company is collaborating in the U.S. with NEXT Oncology, led by Dr. Anthony Tolcher M.D., and Dr. Ildefonso Rodriguez M.D. acts as principal investigator for the San Antonio, TX site. The completion of Cohort 7 in the Phase 1 trial for advanced cancer patients was announced on November 24, 2025.

The network of clinical engagement includes:

• Four U.S. sites activated as of January 2025.
• Three European sites opened in Romania and Bulgaria by January 2025.
• Site activation announced in South Korea in September 2025.
• Completion of Cohort 7 in Phase 1 trial reported November 2025.

Regulatory engagement with the FDA for drug development milestones

Engagement with the U.S. Food and Drug Administration (FDA) is foundational for the PAS-004 program. This relationship was marked by the FDA approval of the Investigational New Drug (IND) application for PAS-004. Furthermore, the FDA reviewed the protocol for the Phase 1 multicenter, open-label trial. The objective of this trial is to assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and to define the preliminary recommended Phase 2 dose. The company also announced a $1 million award from the ALS Association in November 2025 to study PAS-004 for ALS treatment.

Pasithea Therapeutics Corp. (KTTA) - Canvas Business Model: Channels

The distribution and access strategy for Pasithea Therapeutics Corp. (KTTA) centers on clinical development pathways and direct patient access through its subsidiary clinics, leveraging both physical presence and scientific communication.

The primary channel for advancing the lead candidate, PAS-004, is through a multi-center clinical trial network. As of early 2025, this network was strategically expanded to cover key geographies for patient recruitment and data diversity.

Channel Component	Location Type	Count/Status (as of Jan 2025)	Associated Trial/Activity
Clinical Trial Sites	United States	4 open sites	PAS-004 Phase 1 Trial
Clinical Trial Sites	Eastern Europe (Romania and Bulgaria)	3 opened sites	PAS-004 Phase 1 Trial
Total Active Sites	Global	7 total sites	Patient Recruitment

This expansion to seven total clinical sites-four in the US and three in Eastern Europe-was designed to accelerate patient enrollment for the ongoing Phase 1 study of PAS-004.

For direct patient engagement, the wholly owned subsidiary, Pasithea Clinics, utilizes physical locations for in-person treatments. In London, the Company had existing locations in Marylebone and Knightsbridge and planned to open three new clinics by mid-2022, with each clinic projected to contribute an estimated USD$5 million annually in revenue based on 2022 projections. The Company's headquarters is listed in Miami Beach, FL.

Regarding mobile/at-home services, the search results confirm the offering of ketamine therapy at the UK clinic locations, but specific operational details, such as the number of major US cities covered (e.g., NYC, LA, Florida) or associated patient volumes for mobile/at-home IV ketamine services in the US as of late 2025, are not present in the latest filings reviewed.

Dissemination of trial data and corporate visibility is achieved through scientific publications and key industry events. Pasithea Therapeutics Corp. management presented at the H.C. Wainwright 27th Annual Global Investment Conference in New York City between September 8-10, 2025. Furthermore, the Company announced plans to present interim safety and pharmacokinetic (PK) data from PAS-004 Cohorts 4A and 4B in Q1 2025. A significant non-dilutive channel for validation was the $1 Million Award by ALS Association announced on November 25, 2025.

The Channels strategy relies on these distinct avenues:

• - Multi-center clinical trial sites in the US and Eastern Europe for PAS-004, totaling 7 active sites as of January 2025.
• - Pasithea Clinics: Physical locations, including established sites in London (e.g., Marylebone, Knightsbridge) with a projected annual revenue benchmark of USD$5 million per planned new clinic from 2022 estimates.
• - Mobile/At-home IV ketamine services in major US cities (e.g., NYC, LA, Florida), for which specific 2025 operational metrics are not detailed.
• - Scientific publications and conferences (e.g., H.C. Wainwright) to disseminate trial data, with management presenting at the September 2025 conference.

Finance: draft 13-week cash view by Friday.

Pasithea Therapeutics Corp. (KTTA) - Canvas Business Model: Customer Segments

You're looking at the core groups Pasithea Therapeutics Corp. (KTTA) serves or relies on as of late 2025. It's a mix of patients needing novel therapies and the capital markets that fund the science.

The patient segments are defined by the indications for their lead candidate, PAS-004, a next-generation macrocyclic oral MEK inhibitor.

Customer Segment Category	Target Indication/Role	Relevant Statistical/Financial Data Point
Patients with MAPK pathway-driven advanced solid tumors and RASopathies (e.g., NF1)	Advanced Solid Tumors (Phase 1)	As of April 2, 2025, 21 patients had been enrolled in the Phase 1 study. Common diagnoses included pancreatic cancer (28.6%), colorectal cancer (28.6%), and melanoma (23.8%).
Patients with MAPK pathway-driven advanced solid tumors and RASopathies (e.g., NF1)	Neurofibromatosis Type 1 (NF1)	NF1 occurs in about 1 in 3,000 births.
Patients with treatment-resistant mental health disorders (TRD, PTSD)	CNS Disorders Pipeline Expansion	Received a $1 million award from the ALS Association to study PAS-004 in Amyotrophic Lateral Sclerosis (ALS).
Institutional and retail investors funding the clinical-stage biotech pipeline	Financing/Capital Providers	Closed a public offering generating gross proceeds of approximately $60 million on December 2, 2025. The company's enterprise value stood at $117 million in late November 2025.
Academic and research institutions for potential future collaborations	Research & Development Partners	Received a $1 million non-dilutive grant from the ALS Association.

The investor base that participated in the late 2025 financing is specific, showing institutional focus on the clinical-stage assets.

• Healthcare-dedicated investors leading the December 2025 offering included Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management.
• The $60 million gross proceeds from the offering are intended to extend the cash runway through at least the first half of 2028.
• The offering price was set at $0.75 per share of common stock or pre-funded warrant.

For the patient populations, the clinical trial enrollment provides concrete numbers on the initial addressable market being tested.

• In the advanced cancer trial, the efficacy evaluable population was n=16 as of the April 2, 2025 cut-off date.
• One patient with KRAS G12R-mutated pancreatic cancer achieved a tumor diameter reduction of -9.8%.

The academic segment is directly evidenced by the recent grant activity.

• The $1 million ALS Association award supports studying PAS-004 in ALS, expanding the pipeline into a third neurological indication.

Pasithea Therapeutics Corp. (KTTA) - Canvas Business Model: Cost Structure

You're looking at the cost side of Pasithea Therapeutics Corp. (KTTA), and honestly, for a clinical-stage biotech, it's almost entirely driven by the science and the corporate infrastructure needed to support it. The numbers we have, based on the nine months ending September 30, 2025, show where the cash is going before any product revenue starts flowing in.

The biggest chunk of your spending is definitely tied up in the development pipeline, specifically for PAS-004. This is where the money goes to run the clinical trials, which are the make-or-break moments for any drug candidate. You have to fund the science, no way around it.

Here's a quick look at the major operating expenses for the nine months ended September 30, 2025, which gives you a clear picture of the burn rate:

Expense Category	Amount (9 Months Ended Sep 30, 2025)
Research and Development (R&D)	$5,236,320
General and Administrative (G&A)	$5,364,813
Total Reported Operating Expenses (R&D + G&A)	$10,601,133

The General and Administrative (G&A) costs are substantial, reflecting the necessary overhead to operate as a publicly traded entity on NASDAQ. This includes everything from executive salaries to compliance, legal fees, and maintaining that public listing status. It's the cost of being a company, not just a lab.

For the network of Pasithea Clinics, their operating costs-staffing, rent, and supplies for patient care and potentially clinical trial support-are embedded within these reported figures, primarily within the G&A structure, as a separate operating cost line item isn't broken out in the latest filings. You're paying for the infrastructure that supports the CNS disorder focus.

To put the overall financial performance in context, the company was operating at a significant loss, which is typical for this stage of development. The net loss for the trailing 12 months ending September 30, 2025, was approximately -$13.5 million. That's the bottom line you need to cover with financing.

Speaking of financing, you should note the recent capital raise. Pasithea Therapeutics Corp. priced a public offering of 80 million shares at $0.75 each in late November 2025, bringing in around $60 million. This cash infusion is explicitly intended to fund the PAS-004 development and clinical trials, aiming to extend the cash runway through at least mid-2028. That new capital directly offsets the current cost structure by providing a longer operational runway.

Key components driving the R&D spend include:

• Significant Research and Development (R&D) expenses for PAS-004 clinical trials.
• Funding Phase 1 studies for the MEK inhibitor.
• Costs associated with CNS disorder and RASopathies research translation.

The G&A costs cover the corporate necessities:

• Costs associated with maintaining NASDAQ listing compliance.
• Corporate overhead and executive compensation.
• General operational and administrative staffing.

Finance: draft the projected monthly cash burn based on the 9-month operating expense run rate by end of day Tuesday.

Pasithea Therapeutics Corp. (KTTA) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Pasithea Therapeutics Corp. (KTTA) as of late 2025, and honestly, it's what you'd expect from a clinical-stage biotech heavily focused on drug development. The primary financial inflows right now aren't from product sales; they are from financing activities and targeted research support. This is a company funding its pipeline, not yet selling a commercial product.

The most significant recent cash infusion came from the capital markets. Pasithea Therapeutics Corp. priced a public offering of common stock in late November 2025, which closed on December 2, 2025. This move generated gross proceeds of approximately \$60 million before accounting for placement agent fees and other expenses. That capital is key; the company stated the net proceeds are intended to extend its cash runway through at least the first half of 2028.

Beyond equity raises, non-dilutive funding provides crucial, non-equity-cost support for specific research initiatives. For instance, Pasithea Therapeutics Corp. secured a Hoffman ALS Clinical Trial Award grant from the ALS Association worth approximately \$1 million in November 2025. This grant is earmarked specifically to study their lead candidate, PAS-004, in patients with Amyotrophic Lateral Sclerosis.

Here's a quick look at how these major funding events stack up against the company's reported operational revenue status:

Revenue Source Category	Specific Event/Service	Amount/Value	Date/Period
Equity Financing	Public Offering Gross Proceeds	$60 million	Late 2025 (Closed Dec 2, 2025)
Non-Dilutive Funding	ALS Association Hoffman Award	Approximately $1 million	November 2025
Operational Services	Fees for IV ketamine and rTMS services	Fees for IV ketamine and rTMS mental health services from Pasithea Clinics	Ongoing (Pasithea Clinics)
Drug Development Status	Trailing 12-Month Revenue	$0.00	Ending June 30, 2025

The company maintains a revenue stream from its clinical operations, which are separate from the drug development pipeline. This involves the Pasithea Clinics segment. The revenue here is generated from fees for IV ketamine and rTMS mental health services from Pasithea Clinics. Still, the overall picture for the drug development side remains pre-commercial, which is reflected in the official filings.

The official financial reporting confirms the pre-commercial status of the primary business focus. Current trailing 12-month revenue ending June 30, 2025, was reported as \$0.00. This \$0.00 figure is typical for a clinical-stage biotechnology firm whose primary value driver is its pipeline assets, not current sales volume.

To summarize the key components of the Revenue Streams block for Pasithea Therapeutics Corp. as of late 2025, you see a reliance on non-operating income to fuel operations:

• - Capital raising through equity offerings, generating $60 million gross proceeds in late 2025.
• - Non-dilutive grant funding, such as the $1 million from the ALS Association.
• - Fees for IV ketamine and rTMS mental health services from Pasithea Clinics.
• - Current trailing 12-month revenue ending June 30, 2025, was reported as $0.00, reflecting pre-commercial status.